Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anavex Stock Price Crash: A Fault By Trial Design?

Executive Summary

Anavex Life Sciences' unabashed self-promotion since late-2015 for its leading pipeline product ANAVEX 2-73, which is being studied as a treatment for Alzheimer's disease, may have been one reason the firm's stock crashed down this week following the presentation of Phase IIa data at the Alzheimer's Association International Conference. But the study with no control arm and only 32 patients for a neurological disorder also has some analysts questioning how robust the data are.

Advertisement

Related Content

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD

Topics

Advertisement
UsernamePublicRestriction

Register

SC097019

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel